Pfizer price target raised to $32 from $28 at Argus Argus increased its price target on Pfizer after the company reported stronger than expected Q4 results. The firm thinks the company will be launching two promising drugs in the next few weeks and it maintains a Buy rating on the shares.
News For PFE From The Last 14 Days
Check below for free stories on PFE the last two weeks.
